Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gastritis - Overview
Gastritis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Gastritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gastritis - Companies Involved in Therapeutics Development
Addpharma Inc
Allakos Inc
CalyGene Biotechnology Inc
GNT Pharma Co Ltd
Kukje Pharmaceutical Industry Co Ltd
Kyowa Kirin Co Ltd
Otsuka Holdings Co Ltd
Recce Pharmaceuticals Ltd
RedHill Biopharma Ltd
Trio Medicines Ltd
Gastritis - Drug Profiles
AAD-2004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AD-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AD-206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benralizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-20043 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INT-2150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lirentelimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-07 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
netazepide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ondansetron hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rebamipide SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RECCE-327 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RECCE-435 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gastritis - Dormant Projects
Gastritis - Product Development Milestones
Featured News & Press Releases
Oct 26, 2020: Results from prospective prevalence study indicate that eosinophilic gastritis and eosinophilic duodenitis may be significantly underdiagnosed
Oct 26, 2020: Allakos announces results from a phase 1 study of subcutaneously administered lirentelimab (AK002)
Oct 21, 2020: Anti-Siglec-8 Antibody trial shows promise for treating Eosinophilic gastritis and duodenitis
Oct 21, 2020: Allakos announces publication of results from the phase 2 study of lirentelimab (AK002) in patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Jourl of Medicine
Jun 03, 2020: Allakos initiates patient recruitment for AK002 registratiol studies
May 04, 2020: Allakos announces positive interim results from an open-label extension study of Antolimab (AK002) in patients with eosinophilic gastritis and/or eosinophilic duodenitis
Apr 21, 2020: Allakos announces multiple presentations related to eosinophil and mast cell-driven diseases at the 2020 DDW Annual Meeting
Mar 24, 2020: Allakos announces positive phase 1 results with Antolimab (AK002) in Mast Cell Gastrointestil Disease
Oct 28, 2019: Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestil Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting
Aug 05, 2019: Allakos announces AK002 met all prespecified primary and secondary endpoints in phase 2 randomized, double-blind, placebo-controlled study in patients with eosinophilic gastritis (EG) and/or eosinophilic gastroenteritis (EGE)
Oct 08, 2018: Allakos presents data from its eosinophilic gastrointestil diseases program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting
Jun 19, 2017: RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis
Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis
Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results
Mar 02, 2015: Positive Bioavailability Studies of RedHill’s BEKINDA to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Gastritis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020


List of Tables


Number of Products under Development for Gastritis, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Gastritis - Pipeline by Addpharma Inc, H2 2020
Gastritis - Pipeline by Allakos Inc, H2 2020
Gastritis - Pipeline by CalyGene Biotechnology Inc, H2 2020
Gastritis - Pipeline by GNT Pharma Co Ltd, H2 2020
Gastritis - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2020
Gastritis - Pipeline by Kyowa Kirin Co Ltd, H2 2020
Gastritis - Pipeline by Otsuka Holdings Co Ltd, H2 2020
Gastritis - Pipeline by Recce Pharmaceuticals Ltd, H2 2020
Gastritis - Pipeline by RedHill Biopharma Ltd, H2 2020
Gastritis - Pipeline by Trio Medicines Ltd, H2 2020
Gastritis - Dormant Projects, H2 2020